eLearning Evolves into Multimodal Digital Learning in 2019

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” type=”1_1″ first=”true”][fusion_text]

The word “eLearning” has come so far since it was first coined in 1999.[1] Twenty years later, eLearning reaches far beyond the confines of the simple lowercase “e” for electronic. It is highly adaptable, often social and usually competitive. Continuing technological advances in virtual reality, augmented reality, artificial intelligence, and more are transforming the learning experience. eLearning is now multimodal, and its evolution is bringing exciting new trends to learning this year.

2019 Multimodal Digital Learning Trends

Virtual Reality (VR)

VR is a 3D computer-generated environment in which participants can manipulate objects and perform activities. VR most often includes games or simulation exercises that dynamically engage learners while teaching them. It is especially effective in teaching concepts or step-by-step processes. By placing the learner at the very heart of the action, VR also engages multiple senses to reinforce the learning.

Augmented Reality (AR)

In AR the real world is augmented by computer-generated information that changes the participant’s perception. In the world of pharmaceutical and healthcare education, this could include superimposing charts, graphs or other visuals over an otherwise real environment. Anyone who has played Pokémon GO! on their smartphone has experienced augmented reality firsthand.[2]

Mixed Reality (MR)

MR, as it sounds, is a hybrid of VR and AR, but it neither completely immerses the user in the digital world (aka, VR) nor does it layer digital content over the real world (aka, AR). MR enables users to interact with both real objects and 3D virtual objects that appear real, all at the same time. It presents an integration of the virtual with the physical world, and like with AR and VR, it delivers “hands-on” experience, which is important for facilitating learning.[3]

Gamification

Gamification – or competitive learning –  uses game techniques and rewards, such as points, levels and other incentives, to engage and positively influence participant behaviour. It encourages both individual and team-based learning, while increasing factual knowledge by 11% and overall retention rates by 9%. [4] Over 80% of business learners noted in a recent study that gamification helps them to learn and develop professionally.[5] Gamification enables learners to progress or “level up”, and it often incorporates knowledge or skills previously covered, into future activities for reiterative learning. Gamification also encourages collaborative learning, where learners can assist colleagues in order to earn rewards or peer recognition.

Artificial Intelligence (ai)

AI describes the capability of computers to simulate human intelligence, adapting through progressive learning algorithms to become more accurate and intuitive over time. AI is soon to become standard in eLearning. Bots are already guiding learners on their learning path and through their courses.[6] AI will continue to be used to personalize training, as well as to predict learner behaviour and anticipate and adapt to their needs.

Adaptive learning

Adaptive learning is at the top of the 2019 learning trends based on an annual survey by the Learning and Development Global Sentiment.[7] This digital learning approach uses computer algorithms or AI to assess learners on their journey and adapt to their real-time needs. Adaptive learning personalizes the experience by modifying the learning content, as well as its pace and path. Such personalization allows learners to skip past what they demonstrated to already know or mastered and keeps them engrossed in content that is highly relevant and useful to them.[8]

Drip Learning

Drip learning enables instructors or learners to schedule lesson delivery on a drip feed. Once the schedule is set, learners will receive their lessons at a regular pace and in manageable portions. This is especially useful when there is a large amount of knowledge to be consumed and balanced with meeting the regular time demands of a role/job, keeping learners engaged without overwhelming them.

MicroLearning

Microlearning is knowledge and training delivered in short, easily-digestible bursts, such as a 10-minute video or short gamified lesson. Due to its brief nature, microlearning focuses tightly on a topic within a module. It increases retention by 22%[9], compared to traditional longer-form eLearning. In today’s busy lives full of distractions, microlearning is time-efficient and can easily fit between appointments or other tasks.

Video-Based Learning

There is no doubt that video is influential: 60% of YouTube subscribers report being more highly influenced by their favourite creator over their favourite TV or movie celebrity[10] – and that’s because video engages audiences. Forrester research reports that over 75% of employees are more likely to watch a video than read text.[11] Most significantly, video aids in knowledge retention: the average person only remembers one-fifth of what they hear, but introduce visual aids, and learning improves by up to 400%.[12]

Social Learning

The hunger for social media engagement, spurred on by the largest workforce demographic, millennials, has brought a new type of social learning to the fore. Social learning can come in the form of online learning circles, forums and chat sessions. It encourages collaborative learning and knowledge sharing[6], enabling learners to network, exchange ideas and problem solve online, outside of the traditional face-to-face learning environment.

Also spurred on by millennials, mobility will continue to be a trend in 2019, as learners of all generations opt to consume their content on the go. Additionally, learning will become ever more visual-based, since the brain processes visuals 60,000 times faster than text.[12] Content curation will also be a trend to watch, as we see more and more personalization in digital content to suit individual learner needs.

After 20 years, what was once called eLearning has evolved into what we now consider multimodal digital learning, and it is reaching new heights in user engagement and knowledge retention. At Six Degrees Medical Consulting we don’t just coin new phrases for learning, we create learning. We appeal to a broad spectrum of learning types in the design and delivery of our programs. Our team is experienced in working with medical affairs, sales, market access and other stakeholders, to provide dedicated expertise to support and scale training for audiences of any size. Find out more.

Sources

[1] Shift eLearning, ‘10 Great Moments in eLearning History’, https://var/web/site/public_html.shiftelearning.com/blog/bid/343658/10-Great-Moments-in-eLearning-History

[2] Techgenix, ‘Real Deal: mixed reality moves from fantasy world to business world’, http://techgenix.com/mixed-reality-business/

[3] eLearning Inside, ‘Trends in Corporate eLearning Part 1: VR, AR and MR in Learning and Training’, https://news.elearninginside.com/corporate-elearning-realities-part-1-vr-ar-and-mr-in-learning-and-training/

[4] eLearning Guild, ‘Gamification, Games, and Learning: What Managers and Practitioners Need to Know’, http://var/web/site/public_html.elearningguild.com/insights/index.cfm?id=168

[5] Talent LMS, ‘The 2018 Gamification At Work Survey’, https://var/web/site/public_html.talentlms.com/blog/gamification-survey-results/

[6] eLearning Industry, ‘8 Top eLearning Trends For 2019’, https://elearningindustry.com/elearning-trends-for-2019-8-top

[7] L&D ‘GSS 2019 Results’, http://donaldhtaylor.co.uk/ld-gss-2019-the-results/

[8] Matrix, ‘Top eLearning Trends for 2019’, https://var/web/site/public_html.matrixlms.com/info/top_e_learning_trends_for_2019

[9] Journal of Educational Computing Research, ‘Distributing vs. Blocking Learning Questions in a Web-Based Learning Environment’, https://journals.sagepub.com/doi/abs/10.2190/ec.51.4.b

[10] Think with Google, ‘Why YouTube stars are more influential than traditional celebrities’, https://var/web/site/public_html.thinkwithgoogle.com/consumer-insights/youtube-stars-influence/

[11] B2C, ‘10 Reasons to Use Video for Employee Training and Development’, https://var/web/site/public_html.business2community.com/brandviews/wyzowl/10-reasons-to-use-video-for-employee-training-and-development-02080170

[12] 3M, ‘Polishing Your Presentation’, http://var/web/site/public_html.3m.com/meetingnetwork/files/meetingguide_pres.pdf

[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Pharma Trends: What to Expect in 2019

Trends to watch in 2019 include an increasing emphasis on highly targeted drugs; new healthcare applications for artificial intelligence (AI) and machine learning (ML); eMeeting innovations; and pressure to reduce drug prices while improving patient outcomes. The following is a round-up of what we’re expecting to see this year:

Outcome-Based Care

Payers, healthcare professionals and patients will continue to support and demand outcome-based care and treatments. Forbes predicts that by the end of 2019, up to 15% of global healthcare spending will be on outcome-based healthcare and pharmaceutical products.[1]

Pricing

The continued push for outcome-based care will increase the demand for pay-for-performance pricing. This will increase the need for real-world data to back claims about a medicine’s superiority.[2]

Big Data

As pharma companies work on new models that better support outcome-based care, they will be building strategies for collecting and analyzing real-world data to develop the best therapies.[3] Their strategies must also ensure compliance with relevant data privacy laws, such as the EU GDPR and California’s upcoming CCPA.

Personalization and Specialization

Continuing to move away from a one-size-fits-all approach, pharma companies will invest in more novel treatments for rare diseases and move towards personalized medicine[4] and lucrative orphan drugs.

AI and ML

AI in healthcare will top $1.7 billion by the end of the year, gaining traction in drug discovery and risk analytics.[1] AI and ML will further develop human and machine interaction for the benefit of patient health.

Social Media

Social media will continue to help pharma companies deepen relationships with physicians and end consumers. The key challenge will be to do so in compliance with stringent regulations. Younger consumers, especially millennials, choose brands that share their values.[5] Influencer marketing, advocacy and cause marketing will continue to make pharma brands more relevant to them.

IoT

Internet of things (IoT) software and services are expected to reach $2.5 billion by the end of 2019 in the US, growing at a compound annual rate of 42.7% from 2016.[6] The IoT has the potential to bring improvements to all facets of the pharmaceutical industry, including clinical trials, manufacturing, patient monitoring and data collection and analytics.

Edge Computing

Edge computing allows data to be processed closer to where it is created on IoT devices, sensors and mobile technology. Edge devices will continue to be developed to gather, process and analyze data locally in real-time without using the cloud.[7] By by-passing the cloud, they also enable the secure sharing of data directly between devices.

eClinical Trials

Costly on-premise technology will be increasingly replaced by agile, cloud-based eClinical systems for  organizing and conducting clinical trials.[8] It is expected that more patients will enroll in clinical trials as sites become more mobile and flexible, supported by portable and wearable devices, such as health data trackers and electronic diaries. Geography will no longer deter patients from joining clinical trials. They will be able to remain in their own homes with fewer site visits needed.

eMeetings/eLearning

Convenient and cost-effective eMeetings and eLearning will continue to replace their traditional in-person counterparts. Pharma companies will expand their use of virtual platforms for advisory boards, town hall meetings, investigator/site staff training, and disease state and product training to broaden their reach, improve compliance and conserve resources.

Six Degrees Medical understands the importance of keeping up-to-date with industry developments that impact how healthcare organizations do business. We cover a broad range of strategic communications functions, including in-person and eMeetings, key opinion leader management, internal medical training, publication planning, medical writing and more. From project initiation to brainstorming to content development, we employ six proven processes to fully adapt to your needs and deliver measurable results. Find out more here.

[1] Forbes, “Top 8 Healthcare Predictions for 2019”, https://var/web/site/public_html.forbes.com/sites/reenitadas/2018/11/13/top-8-healthcare-predictions-for-2019/#7bdce41d700e

[2]PWC, “Pharma 2020: From Vision to Decision”, https://var/web/site/public_html.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/publications/pharma-2020.html

[3] Pharmaceutical Manufacturing, “Top Pharma Manufacturing Predictions for 2019”, https://var/web/site/public_html.pharmamanufacturing.com/articles/2019/top-pharma-industry-predictions-for-2019/

[4] R&D, “ Outlook 2019: Tech, Data, and Biotech Boom”, https://var/web/site/public_html.rdmag.com/article/2018/10/outlook-2019-tech-data-and-biotech-boom

[5]  Pharma Voice, “2019 Social Media Trends for Pharma”, https://var/web/site/public_html.pharmavoice.com/article/2019-01-social-media-trends/

[6] Global Data, “IoT software and services in the pharmaceutical sector will be worth $2.4 billion by 2020”, https://var/web/site/public_html.globaldata.com/iot-software-services-pharmaceutical-sector-will-worth-2-4-billion-2020-says-globaldata/

[7] Information Age, “Healthcare and edge computing: responsive healthcare”, https://var/web/site/public_html.information-age.com/edge-computing-responsive-healthcare-123476810/

[8] European Pharmaceutical Manufacturer Magazine. “Predictions for pharma in 2019”, https://var/web/site/public_html.epmmagazine.com/opinion/predictions-for-pharma-in-2019/

The FDA’s Streamlined Drug Approval Process: What You Need to Know

Major news from 2018 was the FDA’s announcement of upcoming changes to  the processes of the drug review office. Included in the modernization, per a written statement[1] from the FDA Commissioner Scott Gottlieb, is to provide FDA scientists and medical officers the opportunity to become “thought leaders”[2] in their fields.

The proposals for change include both structural and functional changes. Perhaps the largest change would be the development of a common review template that is built with collaboration in mind. According to the Commissioner, the proposed changes are expected to speed up the approval process for inexpensive generic medications, providing an incentive for second, third, or fourth wave drugs to enter the market.

Among the structural changes, the FDA is considering the creation of therapeutic-specific divisions that would enable specialized focus in discrete areas of medicine. This change would provide increased scientific leadership to academic, industry and patient groups. The FDA is predicting that the new plan will improve efficiency by at least 20%.

The relationship between safety and speed

Not surprisingly, skeptics[3] of the FDA’s decision to streamline processes and prioritize speed have raised concerns about the long-term safety risks inherent in the shorter timelines. In a piece from the New York Times[4], it was argued that efforts to speed a drug to market lower the standard of decision making on the safety and efficacy of the treatment. The commentary’s assertion was that the FDA should prioritize only those drugs with proven long-term benefits in at least two successful clinical trials, which would significantly reduce the risk of false positives.

The FDA maintains that a faster drug review process will be critical to encouraging innovation, and ensuring that breakthrough treatments make it into the hands of the patients who need them. Scott Gottlieb pointed to cancer patients in particular, who do not want to wait three years in order to access a potentially life-saving treatment.

In order to properly assess the increasing number of drugs in future accelerated timeframes, the Office of New Drugs will need to be overhauled. A large part of the overhaul will encourage focused reviews and systems that will increase the efficiency and consistency of the oversight process. 30 specific review divisions will now have nine as opposed to five drug review offices.

Communications challenges abound

As an increasing number of new drugs hit the market in the coming years, establishing an effective communications strategy for each new treatment will become vital; identifying and communicating the key differentiating benefits to stakeholders will be critical to gaining market share.

The medical writing and content development experts at Six Degrees Medical have decades of experience working in an ever-changing regulatory environment. Six Degrees Medical’s skilled team is uniquely equipped to support the pharmaceutical industry and help develop communications strategies aligned with regulatory requirements and company philosophy.

For more information on how Six Degrees Medical can support your organization’s communication efforts following the FDA’s upcoming process changes, contact one of our team members today at +1 647 725-0073.

[1] FDA, “Statement from FDA Commissioner Scott Gottlieb, M.D., on Propose Modernization of FDA’s Drug Review Office”, https://var/web/site/public_html.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609647.htm

[2] Copyright Clearance Centres, “How the FDA Plans to Modernize New Drug Review Process”, http://var/web/site/public_html.copyright.com/blog/fda-new-drugs-review-process/

[3] Pharmexec.com, “Regulatory Innovation Generates Breakthroughs”, http://var/web/site/public_html.pharmexec.com/regulatory-innovation-generates-breakthroughs

[4] New York Times, “Easier Drug Approval Isn’t Cutting Drug Prices”, https://var/web/site/public_html.nytimes.com/2018/06/08/opinion/drug-approval-cutting-prices.html?rref=collection/sectioncollection/opinion-editorials&action=click&contentCollection=editorials&region=stream&module=stream_unit&version=search&contentPlacement=1&pgtype=s

Foundation Set to Enhance the Future of Pharma Industry


[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” first=”true” type=”1_1″][fusion_text]Having worked with pharmaceutical clients for more than a decade, the team at Six Degrees Medical understands the incredible pace of change inherent in the industry. Ongoing changes to regulations, new research and revolutionary new treatment methods require organizations like the ISPE to prioritize innovation. With this in mind, the ISPE has launched a philanthropic arm dedicated to enhancing the organization’s ability to support its members as they “address new and evolving industry demands.”

The ISPE Foundation supports the education, training, and research necessary to advance innovative technologies, and seeks to create solutions to existing challenges in the development, manufacturing, and supply of pharmaceutical products. The foundation sponsors programs that aim to enhance the future of the profession, preparing their members for the challenges of tomorrow.

The foundation is seeking funding to support a wide range of dynamic, mission-focused initiatives, including:

Developing the Future Workforce

Through the ISPE Travel Grant Program[1], the ISPE aims to attract, support, educate, and train young people eager to enter the pharmaceutical industry. In the U.S. alone, 60% of the 3.4 million pharma industry jobs could be vacant by 2025, due to scarcity of young people entering the industry. Given that skill requirements are changing in response to innovation in drug manufacturing, preparedness is key in building the workforce of tomorrow.

Women in Pharma

Currently, only 28% of R&D engineers are female, and they hold board seats on a mere 17% of the top 50 pharma companies. Of that 17%, only 8% are ethnically diverse. This has been proven[2] to negatively impact decision making, employee satisfaction, and consumer orientation. As such, the ISPE Women in Pharma[3] program will provide women with professional training and education to drive successful career progress.

Global Knowledge Exchange

A growing demand for new medicine, combined with emerging markets and technological advances, has produced an overwhelming pace of change in the pharma industry. To overcome the associated challenges, the industry will need to maintain established standards while incorporating new scientific and production quality standards in light of harmonized regulations. The Global Training and Harmonization Fund[4] will support emerging markets through the sharing of best practices, and the transferring of professional knowledge, standards, and expertise.

An Exciting Step Into the Future of Pharma

Particularly as a female-led company, Six Degrees Medical is excited to see the ISPE Foundation supporting the future of the young women entering the pharmaceutical industry. To donate to the ISPE Foundation, or to learn more about each of their specific initiatives, click here.

[1] ISPE Foundation, “https://ispe.org/initiatives/foundation

[2] McKinsey and Company, “Diversity Matters”, https://var/web/site/public_html.mckinsey.com/~/media/mckinsey/business functions/organization/our insights/why diversity matters/diversity matters.ashx

[3] ISPE Foundation, “Women in Pharma”, https://ispe.org/women-pharma

[4] ISPE Foundation, “Emerging Markets Knowledge Exchange”, https://var/web/site/public_html2.ispe.org/iMIS/ISPE/Fundraising/globalknowledgeexchange.aspx[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Will Brexit Create Undue Disruptions to Medical Supply in the UK?

As the UK prepares to exit the European Union, regulatory responsibilities for medication manufacturers are shifting. Companies potentially affected by Brexit need to ensure that their marketing authorisation remains valid in the coming months.

A recent survey[1] conducted by the European Medicines Agency (EMA) showed that 58% of marketing authorisation holders with regulatory ties in the UK are on track with planning to ensure their authorisation remains valid. Since May of 2017, companies have been continuously informed by both the EMA and the European Commission of the need to place necessary measures in motion to maintain the proper certification and avoid medical shortages.

For marketing authorisation holders of centrally authorised products (CAPs), changes to the authorisation itself may be necessary. This could include a transfer of the authorisation to a legal entity located in the European Economic Area (EEA), or the relocation of the qualified person for pharmacovigilance, or pharmacovigilance system master file to a location in the EEA. Changes to logistics, manufacturing sites, supply chains, and contracts may also be necessary in order to maintain authorisation; all of which will require significant time and resources to ensure compliance.

16% of companies are falling short

For 16% of the companies surveyed, the EMA has identified “serious concerns” that actions necessary to maintain authorisation will not be carried out in time. A further 10% of surveyed companies did not provide feedback on their progress.

As a result, the EMA is working directly with companies who have manufacturing facilities inside the UK and did not reply to the survey, or indicated they do not plan to submit the required changes by March 30, 2019. These companies would be required to relocate into the EEA to avoid supply disruptions.

The EMA are now assessing how critical the risks of medical supply shortages are. The EMA’s role is to ensure that it has a complete understanding of the potential supply risks, and to keep the relevant marketing authorisation holders informed in order to mitigate risk.

Guidance from the EMA

The EMA is advising that companies who have not yet informed them of their Brexit plans to do so immediately. They will also be providing continued updates on the status of supply chain risks in the coming months. For more information on the EMA’s Brexit-related guidelines for companies, visit: http://var/web/site/public_html.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_001891.jsp&mid=WC0b01ac0580cb2e5b

Six Degrees Medical understands the importance of keeping up to date with regulatory changes that impact how healthcare organizations do business. The laws affecting the pharmaceutical industry are evolving – and the Six Degrees Medical knowledge base is evolving with them. Leading pharmaceutical companies around the world rely on Six Degrees Medical for insights that translate into customized medical and scientific communications, tailored to suit client-specific objectives. Click here to learn more.

[1] EMA, “EMA Identifies Gaps in Industry Preparedness for Brexit”, http://var/web/site/public_html.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002985.jsp&mid=WC0b01ac058004d5c1

eConnext™: Revolutionize Your Virtual Meetings

VIRTUAL MEETINGS AND PROGRAMS FOR PHARMA, REIMAGINED.

You are busy. Your stakeholders are busy. Your target audience is busy. While nothing will ever replace the value of a face-to-face meeting, the pace of life today demands a more convenient and cost-effective solution. Sure, there are plenty of virtual programs platforms available, but until now, no platform has been able to meet the specific needs of the pharmaceutical industry.

Backed by years of experience developing strategic communications for global pharmaceutical clients, the Six Degrees Medical team began closely examining the specific functionality that would enable a seamless virtual program experience created specifically for the pharmaceutical industry.

Following extensive exploration, our team at Six Degrees Medical is excited to announce the launch of eConnext™, a revolutionary new suite of virtual meetings solutions that deliver unmatched audience engagement through easy, intuitive online environments. The eConnext™ suite utilizes Six Degrees Medical’s unparalleled medical communications expertise to deliver effective solutions customized to meet each client’s unique needs.

The eConnext™ suite includes:

eConnextLive
Create live, large-scale meetings, such as investigator/site staff training to deliver unparalleled engagement through results-oriented communication.

eConnextBridge
Find new ways to engage with your advisory boards, working groups and steering committees through dynamic and convenient meetings and work spaces.

eConnextAcademy
Conduct next-level disease state and product and competitor training across multiple regions at one time.

eConnextForum
Build out your town hall-style meetings to include multiple offices, bringing together your organization like never before.

eConnextOnDemand
Create, house and increase the longevity of your key content and existing assets to maximize opportunities to connect with your target audience using persistent content hosting options.

Why use eConnext™?

Having worked closely with the pharmaceutical industry for well over a decade, Six Degrees Medical has an advanced understanding of the best practices for engaging with and gaining buy-in from the industry’s unique audience. Six Degrees Medical’s experience sets eConnext™ apart from other online meeting programs on the market today, combining flawless execution, medical writing, and pharmaceutical industry content development expertise in a multi-faceted, highly customizable suite of solutions.

Customizable
– Branded to client, company, product, and/or program
– Options to further customize with a branded landing page, functionality, and more

Resource-saving
– Reduce project lifecycle and resource requirements
– Reduce costs associated with venue sourcing and logistics

Convenient
– Track attendee activity and participation
– View reporting of key event metrics at multiple levels

How it works

In partnership with leading technology platform providers, eConnext™ offers end-to-end digital attendee management , from meeting invitation and secure system access to post-meeting evaluation and enduring content hosting. eConnext™ is the only pharma-specific virtual meetings suite that can provide your organization with the opportunity to tailor the platform option to the specific event and desired outcome.

Step 1: Working with you to design the program
– Your strategic input is leveraged to design agendas and meeting structures
– New content is developed and existing content is adapted for online delivery
– Instructional material and audience interactivity is custom-designed to support two-way communication and increase engagement
– Speaker and host training is conducted in line with the program strategy and goals

Step 2: Supporting you as the program rolls out
– Ongoing project management and support in preparation for go live date
– Online platform setup and management
– Live broadcast facilitation and recording
– Ongoing hosting of on-demand content

The convenient way to increase stakeholder engagement

eConnext™ users can expect an integrated virtual program solution that seamlessly blends multiple functionalities into a singular, flawlessly executed, customizable interface, delivered on-strategy, on-budget, and on-time.

eConnext™ can assist your organization in developing engaging and effective global meetings, to find out more, visit the eConnext™ page by clicking on the banner below.

virtual meetings hybrid pharma

Tags: virtual meetings, online programs, all-in-one-solution, pharma-designed, pharmaceutical, virtual medical programs, hybrid meetings.

Developing Key Messaging for Medical Solutions

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” type=”1_1″ first=”true”][fusion_text]The Drug Information Association (DIA) provides a global stage for the discussion of healthcare challenges, within a collaborative and neutral setting. For more than 50 years, stakeholders from around the world have gathered to openly share knowledge and generate new insights. The annual DIA Global Annual Meeting is the largest, longest-running event in the life sciences industry, hosting over 6,000 professionals from the biotechnology, medical device, and pharmaceutical communities, spanning 50 countries and more than 450 exhibiting companies.

At the 2018 DIA, Director of Scientific Content for Six Degrees Medical (SDM), Kristine Jolliffe, PhD, participated in a session titled, “Scientific Communication Key Message Development, Management, and Dissemination”. Featuring two additional speakers (David B. Clemow, PhD, Advisor, Scientific Communications Information Strategy, Eli Lilly and Company and Wesley Portegies, MBA, CEO of Medicalwriters.com), the session provided solutions for optimizing key message development and disclosure, including input/output links, data-to-message mapping, and awareness/access details important for strategic alignment of scientific narratives.

The Current State of Key Messaging

Given how heavily regulated pharmaceutical messaging is, David B. Clemow emphasized in his talk the importance of creating a focused approach. In his opinion, today’s messaging is often chaotic and unplanned. He expressed the need for key messaging to be created through a structured approach, and explained that when the time and effort is put into preparation, it is possible to create effective messaging that is also non-promotional, per regulatory guidelines.

Survey: How Do Neurologists Prefer to Access Key Messages?

In Wesley Portegies’ talk, he detailed a study that his group conducted. In the study, neurologists were asked questions regarding their preference for methods of learning about drug products. Results of the study showed that neurologists prefer to learn drug information from scientific journals, rather than from drug company staff. They prefer this method as they perceive it to be scientifically validated and unbiased.

That being said, this research also proved that the average neurologist only has two hours per week to consume new product information. This significantly limits their time engaging with medical journals. Among Portegies’ proposed solutions are the development of summary videos to accompany articles, which would represent the same material from the scientific journal, but reduce consumption time.

The Future of Key Message Development for Medical Communications

Finally, SDM’s Kristine Jolliffe detailed three anonymized case studies in which SDM has successfully used advisory boards to develop key messaging. As a medical communications agency, SDM has created strategies to help their clients effectively use advisory board meetings as a development space for key messaging.

Advisory boards that work share a number of characteristics:

  • They contain the right advisors. These advisors possess a great deal of expertise, and remain a consistent part of the group over time.
  • They have the right objectives. Their agendas are focused and regionally appropriate.

Utilizing an advisory board to develop key messaging enables organizations to:

  • Interpret scientific data amongst subject matter experts
  • Workshop key messages in a group setting
  • Revisit and hone messaging over time
  • Refine key messaging as new data is released

Within a structured setting, advisors are able to maintain focus as key messagng is developed. And when those advisors are also able to return to the same group setting over time, to re-examine and hone messaging, the resulting communication is effective, up-to-date, and on-strategy.

For more information on SDM’s global medical communications expertise, visit: https://sixdegreesmed.com/.

Interested in learning more about developing key messages? Check out our recent blog on The Advisory Board “Laboratory” for Key Message Development[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Increased Efficiency of Clinical Trials in the EU

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” type=”1_1″ first=”true”][fusion_text]Researchers, stakeholders, and corporate interests reached consensus in 2014 that there needed to be greater harmony of the rules for conducting clinical trials throughout the EU. While there were previous guidelines in place (namely the EU Clinical Trials Directive, which was approved in 2001), member states had interpreted and implemented the rules differently throughout the EU, resulting in increased costs, delays, and various administrative and regulatory burdens.

In response, the EU Clinical Trial Regulation (EU-CTR[1]) entered into force on June 16, 2014. The intention of the regulation is to, “create an environment favourable to conducting clinical trials, with the highest standards of patient safety, for all EU member states”[2]. The regulation includes a number of key provisions:

  • Authorization procedure for clinical trials based on a single submission dossier
  • Assessment procedure for singular decisions on all aspects
  • Rules to guide the protection of subjects
  • Transparency requirements
  • Detailed safety provisions
  • Indemnity provisions
  • Guidelines to support increased multinational trials

Additional transparency requirements clarify the protocol for publishing clinical trial results, and will provide functionality to support such publication through the EU portal and database. The regulation supports the idea that clinical trial study reports should not be confidential, and that instead this information should be made more readily available to the public.

Transparency in the EU

One of the key tenets of the EU-CTR is transparency[3]. The regulation aims to make all information on the EU database publicly available, unless its confidentiality is found to be reasonable under the following 4 conditions:

  • Protecting personal data
  • Protecting confidential communication between EU member states
  • Protecting commercially confidential information
  • Ensuring effective supervision of a trial

Safety Reporting

The regulation makes further specifications around the rules for safety reporting:

  • Not all adverse events may be reported or recorded
  • Clinical trials involving more than one investigational medical product only need to submit a single safety report
  • Suspected Unexpected Serious Adverse Reactions (SUSAR) can be reported to the database.

The Changing Landscape of Clinical Trial Communication

The global medical community has long been moving towards a more transparent landscape, in which data from clinical trials is more readily available to the public. Regulations supporting this assertion have begun popping up across the world, and in order to remain compliant with ongoing legislative changes, pharmaceutical companies need to remain focused on creating a future infrastructure that allows for the publication of a wider range of clinical trial data.

Experts in Medical Communications

At Six Degrees Medical, we are global leaders in translating complex science into knowledge. We understand that the process of introducing a new drug to treat diseases requires not only compliance with regulations such as the EU-CTR, but also high level communication. For over a decade, our team has assisted pharmaceutical clients in optimizing their brand, and streamlining their communications. To learn more about how Six Degrees Medical can improve your company’s communications, call us today at (647) 725-0073, or email us at info@sixdegreesmed.com.

 

[1] Pharmafile, “What You Need to Know About the EU Clinical Trial Regulation”, http://var/web/site/public_html.pharmafile.com/news/198121/what-you-need-know-about-eu-clinical-trial-regulation

[2] European Commission, “Clinical Trials- General Information”, https://ec.europa.eu/health/human-use/clinical-trials/information_en

[3] European Commission, “Clinical Trials- Regulation EU No. 536/2014”, https://ec.europa.eu/health/human-use/clinical-trials/regulation_en[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

eConnext™: Online and Virtual Meetings and Conferences.

eConnext™: Online and Virtual Meetings

TORONTO, CANADA, June 8, 2018— Six Degrees Medical (SDM) announces the launch of eConnext™. eConnext™ combines SDM’s medical writing and pharmaceutical industry content development experience with state-of-the-art online and virtual meetings and conferences platforms to deliver unmatched audience engagement.

Developed by the medical communication professionals who know the needs of pharmaceutical audiences, eConnext™ is an innovative healthcare stakeholder engagement tool offering that provides a full suite of virtual meeting solutions:

eConnextBridge
Advisory Board, Working Group and Steering Committee meetings and workplaces

eConnextLive
Live, large scale meetings such as investigator meetings, medical education events and symposia

eConnextAcademy
Disease state, product training and speaker training events

eConnextForum
Townhall-style meetings, networking events and MSL virtual HCP engagement

eConnextOnDemand
A library of assets to support longitudinal learning

eConnextHub
A comprehensive solution integrating webcasting, webconferencing and additional engagement touchpoints for virtual programs and events

Providing easy, intuitive platforms for online and virtual meetings and conferences, eConnext™ is the next generation of online conference engagement for all pharmaceutical and healthcare company audiences.

Robin Kerbel, CEO and Co-Founder of Six Degrees Medical, comments, “We’ve been working closely with the pharmaceutical industry for well over a decade to help meet the needs of their audiences in the most innovative and engaging ways. eConnext™ is an extension of this, with custom virtual meetings on multiple platforms to deliver the right fit for pharma companies’ current and future program plans.”

Convenient virtual meetings have the power to expand a company’s reach, while cutting costs associated with travel, logistics and out-of-office time. eConnext™ is an innovative suite of virtual meeting solutions that goes beyond simple web conferencing options. In partnership with leading technology platforms, eConnext™ offers end-to-end digital management of participants, from meeting invitation and secure system access to post-meeting evaluation, certification and enduring content hosting. eConnext™ can be tailored to client, company, product and/or program, and features participant tracking and reporting at multiple levels.

Six Degrees Medical provides fully scalable program design, consultation and medical writing, as well as support and engagement strategies for virtual meetings. Their eConnext™ solutions are ideal for KOL content sharing, speaker training and certification, continuing medical education, internal training, and for patient-HCP engagement. eConnext™ is easy to use and intuitive, making clients’ vital content available to audiences any time and from anywhere.

Visit the eConnext™ page

Follow us on LinkedIn

The Advisory Board “Laboratory” for Key Message Development

Medical advisory boards are instrumental in helping companies develop key scientific messages that address unmet needs and best communicate new clinical trial findings. They have become an essential resource for pharmaceutical companies in providing thought leadership, subject matter expertise and scientific direction. By their very design, based on a conversational approach, advisory boards provide key opinion leaders a unique forum in which to express their views and provide recommendations on medical interpretation and scientific communication of new drug data.

The role of medical communications professionals in advisory boards

Careful selection of high-level advisors ensures that these boards are composed of key opinion leaders and influencers in their area of specialization.

Agencies can play an important role in the planning and execution of advisory boards:

  1. As experienced professionals with a well-developed roster of physician contacts, they have long-term relationships with trusted key opinion leaders. This enables them to identify the most appropriate individuals in the sector or disease area for participation in the advisory board;
  2. Expertise to assist the pharmaceutical company in developing an engaging and focused agenda that will ensure that their objectives are achieved and that they gain the best possible insights from the advisors;
  3. Long-standing knowledge of the disease area and product to help create engaging advisory board content and workshop materials designed to promote maximum participation and discussion;
  4. Expert facilitation allowing the pharmaceutical company to concentrate on listening to advisor feedback, or to actively participate in a dialogue, rather than having to focus on facilitating;
  5. Flawless meeting execution by event planning specialists in order to ensure that advisors have a positive experience, and that the pharmaceutical company obtains the input they are seeking from the meeting.

With each of the above elements, the medical communications agency acts as an extension of the pharmaceutical company’s medical affairs team to enhance their in-house capabilities. Members of medical advisory boards become, in effect, strategic partners with the medical communications agencies that organize – and sometimes facilitate – them, as well as with the pharmaceutical companies. In addition, the fact that boards are comprised of healthcare professionals with no vested interest in pharmaceutical manufacturers’ products ensures unbiased insights and objective messaging ideas.

Strategic, effective use of advisory boards

Advisory boards help drug makers identify ways to communicate key scientific information, such as product benefits or side effects that make a real difference to physicians and/or patients.

A variety of processes can be used for message development.  One example is developing “a hierarchy of messaging” in which concepts and phrases are created along thematic lines and then ranked according to importance according to the target audience. Advisors then exchange feedback on these, continually honing them and shuffling their priority. In this scenario, the advisory board acts as a “laboratory” in which ingredients are defined and refined to produce an impactful result to be incorporated into the pharmaceutical company’s scientific communication strategy.

The members’ recommendations are incorporated consistently in publications, scientific communications, educational materials and company communications, even before the time of product launch and beyond. This often takes place over an extended period of time and throughout a product’s life cycle.

Fostering relationships between agencies and pharmaceutical companies

The importance of maintaining close communication and a feedback mechanism between drug companies and medical communications professionals cannot be over-stated. A consistent team of medical writers supporting strategic development of key messages at advisory boards helps provide traction for new products as they enter the marketplace. The agency’s challenge is to create key messaging that is at once scientifically sound and convincing. They act as a mediator between clients and global advisors, ensuring that both sides are heard.

The interface between the medical communications agency and the pharmaceutical company  is ongoing. Agencies at the top of their game know their clients well and understand their communication strategies and style. They are proactive in continually seeking scientific updates and suggesting message refinements as new science emerges.

Well-thought-out advisory boards that are customized to client mandates have become foundational to establishing key messages and communication platforms. They help physicians make treatment decisions for their patients, utilize medications appropriately, and help patients understand the world of science.

About Us

The communications professionals at Six Degrees Medical Consulting have over a decade of experience working with top-tier pharmaceutical companies around the world. We provide our clients the services of a consistent team of medical writers who support medical advisory board execution, including key message development, helping them gain traction for new products.

Contact us today to learn more about how we can put our expertise to work for you in developing your key messages or check out our latest blog, “Six Factors to Consider When Designing Advisory Boards”.